[Federal Register Volume 87, Number 46 (Wednesday, March 9, 2022)]
[Notices]
[Page 13278]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-04970]


-----------------------------------------------------------------------

DEPARTMENT OF COMMERCE

Patent and Trademark Office

[Docket No.: PTO-P-2022-0003]


Grant of Interim Extension of the Term of U.S. Patent No. 
6,953,476; Reducer[supreg]

AGENCY: United States Patent and Trademark Office, Department of 
Commerce.

ACTION: Notice of interim patent term extension.

-----------------------------------------------------------------------

SUMMARY: The United States Patent and Trademark Office has issued an 
order granting a one-year interim extension of the term of U.S. Patent 
No. 6,953,476.

FOR FURTHER INFORMATION CONTACT: Ali Salimi, Senior Legal Advisor, 
Office of Patent Legal Administration, by telephone at 571-272-0909 or 
by email to [email protected].

SUPPLEMENTARY INFORMATION: Section 156 of Title 35, United States Code, 
generally provides that the term of a patent may be extended for a 
period of up to five years if the patent claims a product, or a method 
of making or using a product, that has been subject to certain defined 
regulatory review, and that the patent may be extended for interim 
periods of up to one year if the regulatory review is anticipated to 
extend beyond the expiration date of the patent.
    On February 22, 2022, Neovasc Medical Ltd., the patent owner of 
record, timely filed an application under 35 U.S.C. 156(d)(5) for a 
third interim extension of the term of U.S. Patent No. 6,953,476. The 
patent claims a catheter delivered implantable device, Reducer[supreg]. 
The application for patent term extension indicates that a Premarket 
Approval Application (PMA) P190035 was submitted to the Food and Drug 
Administration (FDA) on December 31, 2019. Review of the patent term 
extension application indicates that, except for permission to market 
or use the product commercially, the subject patent would be eligible 
for an extension of the patent term under 35 U.S.C. 156, and that the 
patent should be extended for one year as required by 35 U.S.C. 
156(d)(5)(B). Because the regulatory review period will continue beyond 
the extended expiration date of the patent, March 27, 2022, interim 
extension of the patent term under 35 U.S.C. 156(d)(5) is appropriate.
    An interim extension under 35 U.S.C. 156(d)(5) of the term of U.S. 
Patent No. 6,953,476 is granted for a period of one year from the 
extended expiration date of the '476 patent.

Robert Bahr,
Deputy Commissioner for Patents, United States Patent and Trademark 
Office.
[FR Doc. 2022-04970 Filed 3-8-22; 8:45 am]
BILLING CODE 3510-16-P